General Characteristics and Pharmacological Properties
This drug belongs to the group of synthetic immunomodulators. Its active pharmaceutical ingredient is aminodihydrophthalazinedione sodium. As a synthetic compound, it features a precisely defined chemical structure that ensures its pharmacological effects in the patient's body.
Clinical pharmacology identifies three key properties of this drug that determine its utility in medical practice. First, it exhibits pronounced immunomodulatory activity, targeting the body's defense systems. Second, the drug demonstrates antioxidant activity, which is an important factor in managing various pathologies. Third, the agent possesses anti-inflammatory effects. The combination of these three pharmacological properties—immunomodulatory, antioxidant, and anti-inflammatory—makes the drug a valuable component in managing infectious diseases.
Mechanism of Action: From Macrophages to Interferons
To understand how aminodihydrophthalazinedione sodium works, one must examine its mechanism of action in detail. The primary site of action is the mononuclear phagocyte system. The drug specifically targets these immune cells, altering their functional activity.
One of the most important manifestations of this action is its effect on phagocytosis. The drug actively stimulates the bactericidal activity of neutrophils. A key pharmacological feature of this agent is that this stimulatory effect is particularly pronounced when the baseline function of these cells is impaired. Under the influence of the drug, neutrophils perform phagocytosis much more efficiently, destroying pathogenic microorganisms.
In addition to its effect on cellular phagocytosis, the drug actively intervenes in the synthesis of defense factors. It reliably increases antibody production in the body. Concurrently, it increases the production of interferons (IFNs). Thus, the drug acts comprehensively, stimulating both cellular mechanisms (neutrophils and macrophages) and the production of protective proteins (antibodies and interferons).
Clinical Application and Contraindications
The key clinical effect for which the drug is prescribed is an increase in nonspecific resistance to infections. In study materials and board review questions, it is often necessary to identify what the drug affects: specific, cellular, or humoral immunity versus nonspecific resistance. The correct answer is the enhancement of the body's nonspecific resistance.
Students must firmly grasp a crucial rule of administration: this immunomodulator is never used as monotherapy. Its use as a standalone treatment is unacceptable. The drug is used exclusively as part of combination therapy for bacterial and viral infections, serving as a component that complements primary treatment.
Like any pharmacological agent, the drug has strict contraindications. Two states are explicitly listed. First is pregnancy. Second, the drug is strictly contraindicated during lactation. Prescribing this agent to patients during these periods is strictly prohibited.